Bulletin of Alexandria Faculty of Medicine. 2004; 40 (2): I-VI
in English
| IMEMR
| ID: emr-65479
ABSTRACT
Between 2001 and 2002, 56 patients with refractory or relapsing non-Hodgkin lymphoma after prior anthracycline based chemotherapy were treated with DHAP [dexamethasone, high dose cytarabine and cisplatin]. After 6 cycles, 28.8% of patients [16/56] achieved complete response, while 58.9% [33/56] attained partial response. The overall survival at 2 years was 25%. Myelosuppression was the major toxicity; 24 patients [42.85%] had grade IV neutropenia and 39 patients [69.64%] had grade III-IV thrombocytopenia, but there was no treatment-related death. DHAP regimen is an effective salvage therapy for the patients with relapsed and refractory NHL, but the response duration time is short and long-term prognosis remains poor; high dose chemotherapy with autologous bone marrow transplantation is necessary for improvement in long-term survival
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Recurrence
/
Dexamethasone
/
Survival Rate
/
Bone Marrow Transplantation
/
Cisplatin
/
Treatment Outcome
/
Cytarabine
/
Drug Combinations
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Bull. Alex. Fac. Med.
Year:
2004
Similar
MEDLINE
...
LILACS
LIS